Postoperative complications and oncologic outcomes after resection of colorectal liver metastases: the importance of staying on track.

Abstract

In a meta-analysis of 2,280 patients who underwent surgery for colorectal liver metastases (CLM) at four major hepatobiliary centers, Matsuda et al. review recent surgical series for which the association between postoperative and long-term outcomes was reported. Despite major advances in liver surgery in the past two decades, during which 30-day mortality decreased to 2.4 % nationally for hepatectomies, the authors emphasize the continued high rate (*40–50 %) of postoperative complications, which occur more frequently with operations of greater magnitude, or in association with comorbidities. Whether the association between complications and survival is the result of a direct cause-effect relationship or a reflection of more extensive surgery being performed for greater tumor burden (which would negatively affect survival) cannot be proven, but the merit of this analysis is that it brings to the forefront the need for ‘‘staying on track’’ in hepatobiliary oncology, i.e., making sure that patients complete the recommended multiple stages of treatment. This is particularly relevant in cancer patients who need multidisciplinary therapy because veering off track will delay additional treatment, whether it is chemotherapy, radiation therapy, or a planned second-stage operation. As such, the return to intended oncologic therapy (any form) and, similarly, the return to full preoperative performance status are major endpoints that are currently underreported in most outcome studies on surgical morbidity. So, if we accept the conclusions of the authors, how do we ‘‘stay on track’’ in order to decrease complications in the surgical treatment of CLM? The first modifiable risk factor is the duration of preoperative chemotherapy, which is increasingly used for CLM. Chemotherapy for an extended duration ([8 cycles) only increases the risk of chemotherapy-associated liver injury and postoperative complications without improving pathologic response. Thus, every patient with CLM who might be a candidate for surgery (this includes patients with ‘‘initially unresectable’’ CLM who have bilateral disease, small livers, or resectable extrahepatic disease) should be evaluated at diagnosis by a multidisciplinary team that includes a hepatobiliary surgeon. The goal of chemotherapy is not and should not be complete disappearance of the CLM. Effective first-line chemotherapy should be used, because multiple lines of chemotherapy are associated with inferior survival. A second method of decreasing morbidity is the sequencing of operations in the setting of synchronous CLM with intact primary colorectal cancer. The liver-first, or reverse, approach allows the less contaminated operation to be done before resection of the primary while clearing the patient of metastatic disease. As an option for patients with nonobstructing primary tumors, this is usually chosen for patients requiring neoadjuvant chemotherapy and larger hepatic resections for CLM that are the dominant lifelimiting process (rather than the primary lesion) for the patient. The reverse approach should be considered in the subset of patients who require major (right) liver resection with the primary in place, because the mortality and morbidity of combined resection of liver and primary is markedly increased in these patients. Concerns about the morbidity of major colorectal operations, even proctectomies, staged after major hepatectomies should not preclude reverse-approach sequencing. Third, dividing extended hepatectomies into two stages continues to be a viable option in patients with bilateral CLM. Staged resection is recommended for any of the following situations: inadequate future liver remnant (FLR), medical comorbidities precluding longer operative time for simultaneous resection of the CLM and primary Society of Surgical Oncology 2013